explore -WSS

explore

author：Wikipedia 2025-10-03 00:04:18 - browse：83

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： NYU Langone launches private ChatGPT for its health care data

WSS

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Radiation, mainstay of cancer treatment, begins a fade

Neuroscience startup Neumora files for IPO

Departing Stanford president retracts two papers

An inside look at PIPEs, biotech's buzzy new financing tool

Drug firms test therapies to halt Alzheimer’s before symptoms arise

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

FogPharma raises $145 million in rare Series E round

Medical leaders decry Supreme Court decision on affirmative action

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Psilocybin's anti

Apple is now the first public company to be valued at $3 trillion

Winners, losers from Medicare’s list of drugs subject to price talks

Continuity nursing helped my family in our darkest PICU moments

Biotech companies concerned about China biosecurity crackdown

leisure time

Psilocybin's anti

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Obesity now affects over 1 billion people worldwide, study finds

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Why getting cancer drugs just got harder for rural patients

Complete sequence of Y chromosome published for first time

focus

knowledge

hotspot

hotspot